Open AccessInfigratinib (Truseltiq®)
Author(s) -
Michelle Sproat
Publication year - 2022
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000839944.24360.6f
Subject(s) - medicine , fibroblast growth factor receptor , regimen , cohort , oncology , progressive disease , tyrosine kinase inhibitor , receptor tyrosine kinase , cancer , gastroenterology , fibroblast growth factor , chemotherapy , receptor